A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

This is a randomized, open-label, multi-center, phase III study to evaluate the efficacy and safety, and immunogenicity of MRG003 in combination with pucotenlimab in patients with recurrent or metastatic nasopharyngeal carcinoma.

Trial Details

NCT ID
NCT06976190
Phase
PHASE3
Sponsor
Lepu Biopharma Co., Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • MRG003 + Pucotenlimab
  • Gemcitabine, Docetaxel, or Capecitabine
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Willing to sign the informed consent form and follow the requirements specified in the protocol.
  • Life expectancy ≥ 12 weeks.
  • Patients with histologically and cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma (NPC) who have failed at least one line o…
  • Patients must have at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →